INPPL1 and breast carcinoma: While these studies portend a role for SHIP2 inhibitors in breast cancer treatment, the thiophenes 1 and 2 are generally regarded to have poor pharmacodynamic properties [143], which is common in small molecule leads but precludes clinical development.